FindTrial
Sign In

Anti Thymocyte Globulin

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Paul Szabolcs, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

Diffuse Sclerosis SystemicInterstitial Lung DiseaseNeuroblastomaPulmonary HypertensionRenal Function and Chronic Allograft VasculopathySystemic Sclerosis

Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RecruitingNCT03630211
Paul SzabolcsDiffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension +1
Start: 2018-07-31End: 2026-08-01Target: 8Updated: 2025-10-15
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Not yet recruitingNCT05303727
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeuroblastoma
Start: 2022-08-31End: 2027-08-31Target: 64Updated: 2022-07-01

Phase 4

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
CompletedNCT01266148
Novartis PharmaceuticalsRenal Function and Chronic Allograft Vasculopathy
Start: 2009-11-30End: 2012-12-31Updated: 2015-06-10

Related Papers

Autologous Stem Cell Transplantation (ASCT) for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) Is Safe and Well Tolerated and Improves Clinical and Patient-Reported Outcomes
Blood2022-11-151 citations
Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression.
2018-11-0510 citations
Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients
Circulation Heart Failure2018-09-0152 citations